|
A National Registry on Chinese Patients With Lymphangioleiomyomatosis
RECRUITINGSponsored by Peking Union Medical College Hospital
Actively Recruiting
SponsorPeking Union Medical College Hospital
Started2017-01-01
Est. completion2026-10-01
Eligibility
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03193892
Summary
Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.
Eligibility
Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria: 1. Gender: female. 2. Age: no limitation. 3. Diagnosis meets one of the following criteria, (1) definite or probable diagnosis of LAM based on ATS/JRS and ERS criteria. (2) Investigators recommend including of the patient. Exclusion Criteria: 1. Suspected LAM patients without other supporting evidence for LAM diagnosis. 2. No diffuse cystic lesions in the lung. 3. Patients with bilateral cystic lung lesions but the LAM diagnosis cannot be established. 4. Without signed informed consent. 5. Difficult to follow up.
Conditions3
CancerLung CancerPulmonary Function
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorPeking Union Medical College Hospital
Started2017-01-01
Est. completion2026-10-01
Eligibility
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03193892